Brokerages Expect Tcr2 Therapeutics Inc (NASDAQ:TCRR) to Post -$0.65 Earnings Per Share

Equities research analysts predict that Tcr2 Therapeutics Inc (NASDAQ:TCRR) will report earnings per share of ($0.65) for the current quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Tcr2 Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.62) and the lowest estimate coming in at ($0.67). Tcr2 Therapeutics posted earnings per share of ($16.22) in the same quarter last year, which suggests a positive year over year growth rate of 96%. The company is expected to announce its next quarterly earnings report on Monday, April 6th.

According to Zacks, analysts expect that Tcr2 Therapeutics will report full-year earnings of ($5.10) per share for the current fiscal year, with EPS estimates ranging from ($6.56) to ($4.32). For the next year, analysts expect that the company will report earnings of ($2.76) per share, with EPS estimates ranging from ($3.21) to ($1.91). Zacks Investment Research’s earnings per share averages are an average based on a survey of research firms that follow Tcr2 Therapeutics.

Tcr2 Therapeutics (NASDAQ:TCRR) last issued its earnings results on Tuesday, November 12th. The company reported ($0.58) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.55) by ($0.03).

A number of equities analysts recently weighed in on the stock. ValuEngine downgraded shares of Tcr2 Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, September 27th. Zacks Investment Research downgraded shares of Tcr2 Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, November 16th. Finally, HC Wainwright restated a “buy” rating and set a $19.00 target price on shares of Tcr2 Therapeutics in a report on Wednesday, December 11th. Three research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $25.00.

In other Tcr2 Therapeutics news, major shareholder Morana Jovan-Embiricos sold 139,989 shares of Tcr2 Therapeutics stock in a transaction on Monday, December 9th. The shares were sold at an average price of $17.65, for a total transaction of $2,470,805.85. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last ninety days, insiders have sold 154,511 shares of company stock valued at $2,708,823. Company insiders own 39.07% of the company’s stock.

A number of hedge funds have recently added to or reduced their stakes in the business. Barclays PLC boosted its position in Tcr2 Therapeutics by 402.1% during the third quarter. Barclays PLC now owns 5,885 shares of the company’s stock worth $89,000 after purchasing an additional 4,713 shares during the period. Parametric Portfolio Associates LLC boosted its position in Tcr2 Therapeutics by 23.5% during the second quarter. Parametric Portfolio Associates LLC now owns 35,044 shares of the company’s stock worth $501,000 after purchasing an additional 6,672 shares during the period. Rhumbline Advisers bought a new position in Tcr2 Therapeutics during the third quarter worth $162,000. California State Teachers Retirement System boosted its position in Tcr2 Therapeutics by 568.2% during the third quarter. California State Teachers Retirement System now owns 18,254 shares of the company’s stock worth $274,000 after purchasing an additional 15,522 shares during the period. Finally, EcoR1 Capital LLC bought a new position in Tcr2 Therapeutics during the second quarter worth $231,000. 42.15% of the stock is owned by hedge funds and other institutional investors.

TCRR traded up $0.41 during trading on Tuesday, reaching $14.50. 58,300 shares of the stock were exchanged, compared to its average volume of 95,878. The stock has a market cap of $370.12 million and a P/E ratio of -0.15. Tcr2 Therapeutics has a twelve month low of $10.04 and a twelve month high of $25.47. The stock’s 50 day moving average price is $16.08 and its two-hundred day moving average price is $15.49.

Tcr2 Therapeutics Company Profile

TCR2 Therapeutics Inc, a clinical-stage immunotherapy company, develops novel T cell receptor therapies for patients suffering from cancer. Its product candidates in pipeline comprise TC-210 mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors; TC-220 that targets MUC16 positive solid tumors; and TC-310 and TC-410 dual TRuC-T cell programs targeting CD19/22 and MSLN/MUC16, as well as TC-110 mono TRuC-T cells targeting CD19-positive B-Cell hematological malignancies.

See Also: Stock Portfolio Tracker

Get a free copy of the Zacks research report on Tcr2 Therapeutics (TCRR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Tcr2 Therapeutics (NASDAQ:TCRR)

Receive News & Ratings for Tcr2 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tcr2 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.